My family moved to the US when I was 8, but by the time I turned 20, my dad was still on an H1B (waiting to get processed for a green card). Once I turned 21, I would age out as his dependent, despite the fact that I basically grew up in the US. I thought I'd have to become a

in ~15 years, metastatic melanoma went from a disease with a median 6 month survival time to one where 52% of patients have melanoma-specific survival 10 years out may we all get a chance to work on medical technologies like this - my god! nejm.org/doi/full/10.10…

The NIH is broken. Much of $50 billion a year funds bureaucracy, political nonsense, and academic welfare instead of breakthrough science. America needs to slash the red tape, fund bold ideas, and stop rewarding mediocrity if we want to lead the next golden age of science. 🧵

wow. this is so good and funny - watch till the end.

SO PROUD of the ⁦City Therapeutics⁩ forming their 2nd major alliance!!!! This time with ⁦@Biogen⁩ for a CNS target, w/ $46M upfront and >$1B in total deal value! Combined with earlier ⁦Bausch + Lomb⁩ deal, City is growing strong in a tough tape! globenewswire.com/news-release/2…

BIG NEWS! Ashlee Vance just profiled the first parents with not one — but two— Orchid superbabies. This is just the beginning. Every child, genetically blessed from day one.

congrats Brandon and the Axiom team. Scale of the platform/data is so impressive..

One-month update of Biomni⬇️ Excited to see how Biomni has automated 15K+ research tasks for biologists!

📢 Call for proposals: Boltz small-molecule design collaboration! 🧬 Can we help design your ideal molecule? Can you help us improve our open-source models? Please reach out or share with scientists you know! More details below! It has been great to see the level of excitement

why don’t we have more medicines? inventing medicines has grown less efficient, limited by our knowledge of biological targets for the 1st time, AI & genomics have the potential to make this knowledge abundant – one of the largest potential impacts of the intelligence age.

🚨 Just dropped! GREmLN is a graph-based transformer model that uses the molecular logic of cells to enable insights into disease states. This nimble model accounts for causality + locality using gene regulatory networks📄 Read the preprint: bit.ly/44lLF8x

So, who decides what deserves our attention? interesting thread on issues re scientific content consumption. there is much larger problem - how do you find, assess and consume quality papers?

Insightful essay - worth the time reading this… “AI discourse in science in the context of production-progress paradox.”

I just published my weekly reflections: docs.google.com/document/d/1Gr… . An IDE for your life. Sycosocial. Memetic gain-of-function.The News Feed Betrayal effect. Human computing. The Philosopher-Builder. Synergistic Satisfiers. Polychrome quilt. Chocolate and Peanut Butter

If we don’t change how we develop drugs in the US we’re going to lose the industry

It feels like there are two modalities of competition in Silicon Valley today. Both are valid and interesting and can lead to big outcomes. Modality 1: Work on something legible. Out execute the fuck out of everyone. --> This means that you are working on something that is

ok :)

The FDA just updated the approval for Inclisiran—a small-interfering RNA therapy for cholesterol—by making it a front-line therapy. Now, with just two shots a year rather than with daily statin dosing, practically anyone can achieve healthy LDL. Long-acting drugs are winning!

100% , with an emphasis on “novel therapeutics” that can be defended…

We put a blog post together to tell you about all that went behind the scenes for Arc Institute's Virtual Cell Challenge: (1) the modality used for genetic perturbations, (2) choice of single cell RNA seq chemistry, (3) which cell line to use for the challenge, (4) which genes to